NKTR
NASDAQ HealthcareNektar Therapeutics - Common Stock
Biotechnology
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
๐ Market Data
| Price | $86.46 |
|---|---|
| Volume | 689,763 |
| Market Cap | 2.92B |
| Beta | 1.180 |
| RSI (14-Day) | 57.3 |
| 200-Day MA | $53.77 |
| 50-Day MA | $76.83 |
| 52-Week High | $109.00 |
| 52-Week Low | $7.99 |
| Forward P/E | -8.01 |
| Price / Book | 19.61 |
๐ฏ Investment Strategy Scores
NKTR scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (63/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ช Falling Knife (10/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find NKTR in your text
Paste any article, transcript, or post โ the tool will extract NKTR and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.